Sort
39,280 grants matching “leukemia”
Clinical and Molecular Heterogeneity in the Myelodysplastic Syndromes
$685,543Christopher Y Park · New York University School Of Medicine · R01 · FY2023 · CA
Protein Microcharacterization Core Facility
$685,399Kenneth Tomer · Environmental Health Sciences · Z01 · FY2007 · ES
Understanding the role of the blood vascular system and endothelial cells in early thymus regeneration after cytotoxic treatments using novel intravital imaging techniques
$684,794Joel A. Spencer · University Of California, Merced · R01 · FY2024 · HL
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
$684,584Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie
$684,551Clara D Bloomfield · Ohio State University · U10 · FY2018 · CA
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
$684,513Paul W. Burridge · Northwestern University At Chicago · R01 · FY2021 · CA
Hematalogical Malignancies
$684,494Richard James Gilbertson · St. Jude Children'S Research Hospital · P30 · FY2015 · CA
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
$684,230Jianjun Chen · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
iPSC-based blood regenerative therapies for AIDS
$684,039Igor I Slukvin · University Of Wisconsin-Madison · R01 · FY2015 · HL
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy
$683,754A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2012 · CA
An INteractive Survivorship Program to Improve Healthcare REsources [INSPIRE] for Adolescent and Young Adult (AYA) Cancer Survivors
$683,516Kevin S Baker · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
Pharmacodynamically directed targeted therapy for leukemia
$683,472John C Byrd · University Of Cincinnati · R01 · FY2025 · CA
Synthetic introns for selective targeting of RNA splicing factor-mutant leukemia
$683,443Robert K Bradley · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
$683,255Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2023 · CA
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
$683,255Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2022 · CA
Third-party âoff the shelfâ mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
$683,230Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2019 · HL
Enhancing Treg Therapeutic Efficacy in GVHD
$683,148Bruce R. Blazar · University Of Minnesota · R01 · FY2025 · HL
Development of Recombinant Toxins to Treat Hematologic Malignancies
$683,093Robert Kreitman · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Bioinformatic Tools in Cancer Research
$683,082Kenneth Buetow · Division Of Basic Sciences - Nci · ZIH · FY2010 · CA
Cancer and Leukemia Group B Statistical Center
$682,887Stephen L George · Duke University · U10 · FY2009 · CA
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy
$682,792A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2014 · CA
Immunogenetic determinants of cancer risk
$682,727Robert M Samstein · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Establishing Mixed Hematopoietic Chimerism in a Canine Model
$682,585Rainer F. Storb · Fred Hutchinson Cancer Research Center · P01 · FY2010 · CA
Statistical Informatics for Cancer Research
$682,555Xihong Lin · Harvard School Of Public Health · P01 · FY2009 · CA
SELECTIVE TARGETING OF MUTANT SHP2 ONCOPROTEINS IN RARE LEUKEMIAS
$682,472Sanford Burnham Prebys Medical Discovery Institute · · FY2024 · Defense Health Agency